Trial Profile

A phase 3 retrospective study of Tesamorelin in Hypercholesterolaemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tesamorelin (Primary)
Indications Hypercholesterolaemia
Focus Pharmacodynamics

Most Recent Events

09 Oct 2024 According to Thera Technologies media release, impact of Tesamorelin on cardiovascular disease risk prediction scores in Phase 3 Studies treatment arms: Subanalysis, will be presented in a poster session at IDWeek 2024, on Thursday, October 17, 2024, 12:15 PM -1:30 PM PT.
05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com